Introduction/Background The aim of this study was to evaluate the oncologic and reproductive outcomes after fertility-sparing surgery (FSS) in young women with malignant ovarian germ cell tumor (MOGCT).
Methodology The medical records of women aged under 40 years with MOGCT who underwent surgery at our institution between July 2002 and December 2017 were retrospectively reviewed. FSS was defined as the preservation of the uterus and at least one adnexa.
Results A total of 44 patients who underwent FSS were included. The median age of patients was 23 years (range, 7–39 years). There were 20 patients (45.5%) with immature teratoma, 13 (29.5%) with dysgerminoma, 6 (13.5%) with endodermal sinus tumor, 3 (6.8%) with mixed germ cell tumor, 1 with choriocarcinoma, and 1 with embryonal carcinoma. 29 patients (65.9%) received postoperative chemotherapy with bleomycin, etoposide, and cisplatin (BEP). During a median follow-up period of 62.5 months (range, 7–185), only 4 patients (9.1%) had a recurrence. Notably, all of 2 patients with dysgerminoma had recurrence at para-aortic lymph nodes and all of 2 patients with grade-2 immature teratoma had recurrence at contralateral ovary. Of 14 women desiring pregnancy, 12 achieved term delivery of 12 singleton pregnancies. The pregnancy rate was 85.7% and the live birth rate was 100%.
Conclusion Fertility-sparing surgery is an acceptable option for young patients with MOGCT who wish to preserve their fertility, provided they are willing to undergo a prolonged follow up. Reproductive outcomes are assuring to them.
Disclosure Nothing to disclose.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.